Comparison of Monthly Ibandronate Versus Weekly Risedronate in Preference, Convenience, and Bone Turnover Markers in Korean Postmenopausal Osteoporotic Women

被引：14

作者：

Chung, Yoon-Sok ^{[2
]}

Lim, Sung-Kil ^{[1
]}

Chung, Ho-Yeon ^{[3
]}

Lee, In-Kyu ^{[4
]}

Park, Il-Hyung ^{[5
]}

Kim, Ghi-Su ^{[6
]}

Min, Yong-Ki ^{[7
]}

Kang, Moo-Il ^{[8
]}

Chung, Dong-Jin ^{[9
]}

Kim, Yong-Ki ^{[10
]}

Choi, Woong Hwan ^{[11
]}

Shong, Min Ho ^{[12
]}

Park, Ji-Hyun ^{[13
]}

Byun, Dong-Won ^{[14
]}

Yoon, Hyun-Koo ^{[15
,16
]}

Shin, Chan Soo ^{[17
]}

Lee, Yil-Seob ^{[18
]}

Kwon, Nam-Hee ^{[19
]}

机构：

[1] Yonsei Univ, Coll Med, Dept Internal Med, Div Endocrinol & Metab, Seoul 120752, South Korea

[2] Ajou Univ, Sch Med, Dept Endocrinol & Metab, Suwon 441749, South Korea

[3] Kyung Hee Univ, Dept Internal Med, Div Endocrinol & Metab, Seoul, South Korea

[4] Kyungpook Natl Univ, Sch Med, Dept Internal Med, Taegu, South Korea

[5] Kyungpook Natl Univ, Sch Med, Dept Orthoped Surg, Taegu, South Korea

[6] Asan Med Ctr, Dept Internal Med, Div Endocrinol & Metab, Seoul, South Korea

[7] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Div Endocrinol & Metab,Dept Med, Seoul, South Korea

[8] Catholic Univ Korea, Seoul St Marys Hosp, Dept Internal Med, Div Endocrinol & Metab, Seoul, South Korea

[9] Chonnam Natl Univ, Sch Med, Dept Internal Med, Div Endocrinol & Metab, Kwangju, South Korea

[10] Pusan Natl Univ, Coll Med, Dept Internal Med, Div Endocrinol & Metab, Pusan 609735, South Korea

[11] Hanyang Univ, Dept Internal Med, Div Endocrinol & Metab, Seoul 133791, South Korea

[12] Chungnam Natl Univ, Dept Internal Med, Div Endocrinol & Metab, Taejon, South Korea

[13] Chonbuk Natl Univ Hosp, Dept Internal Med, Div Endocrinol & Metab, Jeonju, South Korea

[14] SoonChunHyang Univ Hosp, Dept Internal Med, Div Endocrinol & Metab, Seoul, South Korea

[15] Kwandong Univ, Cheil Gen Hosp, Div Endocrinol & Metab, Dept Internal Med,Coll Med, Seoul, South Korea

[16] Womens Healthcare Ctr, Seoul, South Korea

[17] Seoul Natl Univ, Coll Med, Dept Internal Med, Div Endocrinol & Metab, Seoul 151, South Korea

[18] GlaxoSmithKline Korea, Seoul, South Korea

[19] GlaxoSmithKline Asia Pacific, Singapore, Singapore

来源：

CALCIFIED TISSUE INTERNATIONAL | 2009年 / 85卷 / 05期

关键词：

Ibandronate; Risedronate; Preference; Convenience; Korean; MONTHLY ORAL IBANDRONATE; ONCE-WEEKLY ALENDRONATE; PATIENT PREFERENCE; FRACTURE RISK; MINERAL DENSITY; OPEN-LABEL; PERSISTENCE; BISPHOSPHONATES; TOLERABILITY; ADHERENCE;

D O I：

10.1007/s00223-009-9294-y

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Patient preferences, convenience, and bone turnover markers were evaluated for the monthly ibandronate over the weekly risedronate regimen in Korean postmenopausal osteoporotic women. This was a 6-month, prospective, randomized, open-label, multicenter study with a two-period and two-sequence crossover treatment design. After a 30-day screening period, eligible participants with postmenopausal osteoporosis were randomized to receive either monthly oral ibandronate 150 mg for 3 months followed by weekly oral risedronate 35 mg for 12 weeks (sequence A) or the same regimen in reverse order (sequence B). Patient preference and convenience were evaluated by questionnaire. The changes in serum C-telopeptide after 3 months of treatment were analyzed. A total of 365 patients were enrolled in this study (sequence A 182, sequence B 183). Of patients expressing a preference (83.4%), 74.8% preferred the monthly ibandronate regimen over the weekly regimen (25.2%). More women stated that the monthly ibandronate regimen was more convenient (84.2%) than the weekly regimen (15.8%). There was no significant difference in the change in bone turnover marker between the two treatments. The two regimens were similarly tolerable. There were fewer adverse events in the monthly ibandronate group compared to the weekly risedronate group in terms of gastrointestinal side effects (nausea and abdominal distension). This study revealed a strong preference and convenience for monthly ibandronate over weekly risedronate in Korean postmenopausal osteoporotic women. There was no significant difference in change of bone turnover marker and safety profile between the two regimens.

引用

页码：389 / 397

页数：9

共 34 条

[1]

BARTL R, 2005, OSTEOPOROS INT S3, V16, pS45

[2] Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis [J].

Chesnut, CH ;

Skag, A ;

Christiansen, C ;

Recker, R ;

Stakkestad, JA ;

Hoiseth, A ;

Felsenberg, D ;

Huss, H ;

Gilbride, J ;

Schimmer, RC ;

Delmas, PD .

JOURNAL OF BONE AND MINERAL RESEARCH, 2004, 19 (08) :1241-1249

[3] A systematic review of the associations between dose regimens and medication compliance [J].

Claxton, AJ ;

Cramer, J ;

Pierce, C .

CLINICAL THERAPEUTICS, 2001, 23 (08) :1296-1310

[4] Treatment persistence with once-monthly ibandronate and patient support vs. once-weekly alendronate: results from the PERSIST study [J].

Cooper, A. ;

Drake, J. ;

Brankin, E. .

INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2006, 60 (08) :896-905

[5] HIP-FRACTURES IN THE ELDERLY - A WORLDWIDE PROJECTION [J].

COOPER, C ;

CAMPION, G ;

MELTON, LJ .

OSTEOPOROSIS INTERNATIONAL, 1992, 2 (06) :285-289

[6]

Cramer JA, 2004, J BONE MINER RES, V19, pS448

[7] RisedronatE and ALendronate Intervention over Three Years (REALITY): minimal differences in fracture risk reduction [J].

Curtis, J. R. ;

Westfall, A. O. ;

Cheng, H. ;

Saag, K. G. ;

Delzell, E. .

OSTEOPOROSIS INTERNATIONAL, 2009, 20 (06) :973-978

[8] Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study [J].

Delmas, PD ;

Recker, RR ;

Chesnut, CH ;

Skag, A ;

Stakkestad, JA ;

Emkey, R ;

Gilbride, J ;

Schimmer, RC ;

Christiansen, C .

OSTEOPOROSIS INTERNATIONAL, 2004, 15 (10) :792-798

[9] Upper gastrointestinal and overall tolerability of alendronate once weekly in patients with osteoporosis: results of a randomized, double-blind, placebo-controlled study [J].

Eisman, JA ;

Rizzoli, R ;

Roman-Ivorra, J ;

Lipschitz, S ;

Verbruggen, N ;

Gaines, KA ;

Melton, ME .

CURRENT MEDICAL RESEARCH AND OPINION, 2004, 20 (05) :699-705

[10] Patient preference for once-monthly ibandronate versus once-weekly alendronate in a randomized, open-label, cross-over trial: the Boniva Alendronate Trial in Osteoporosis (BALTO) [J].

Emkey, R ;

Koltun, W ;

Beusterien, K ;

Seidman, L ;

Kivitz, A ;

Devas, V ;

Masanauskaite, D .

CURRENT MEDICAL RESEARCH AND OPINION, 2005, 21 (12) :1895-1903

← 1 2 3 4 →